NO821496L - Befruktningshindrende gelpreparat. - Google Patents
Befruktningshindrende gelpreparat.Info
- Publication number
- NO821496L NO821496L NO821496A NO821496A NO821496L NO 821496 L NO821496 L NO 821496L NO 821496 A NO821496 A NO 821496A NO 821496 A NO821496 A NO 821496A NO 821496 L NO821496 L NO 821496L
- Authority
- NO
- Norway
- Prior art keywords
- approx
- preparation
- preparation according
- inhibitor
- pharmaceutically acceptable
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 61
- -1 polyoxyethylene Polymers 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 230000004720 fertilization Effects 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 230000003915 cell function Effects 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 229920001400 block copolymer Polymers 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 229910052717 sulfur Chemical group 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- CLEDFOUEAGECMZ-UHFFFAOYSA-N 1-[2-[(2,4-dichlorophenyl)methoxy]octyl]imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=C(Cl)C=C(Cl)C=1COC(CCCCCC)CN1C=CN=C1 CLEDFOUEAGECMZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 230000003509 anti-fertility effect Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000001150 spermicidal effect Effects 0.000 description 9
- 229920001983 poloxamer Polymers 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940124558 contraceptive agent Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- GPUZWNNASIXLTQ-UHFFFAOYSA-N 1h-imidazole;oxalic acid Chemical compound C1=CNC=N1.OC(=O)C(O)=O GPUZWNNASIXLTQ-UHFFFAOYSA-N 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 230000000469 anti-sperm effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940087419 nonoxynol-9 Drugs 0.000 description 2
- 229920004918 nonoxynol-9 Polymers 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- 239000000934 spermatocidal agent Substances 0.000 description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
- NHALCNDHRJDLNC-UHFFFAOYSA-N 1-(2-ethylsulfanyltetradecyl)imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCCCCCCC(SCC)CN1C=CN=C1 NHALCNDHRJDLNC-UHFFFAOYSA-N 0.000 description 1
- CMZZJAGYGMXLAC-UHFFFAOYSA-N 1-(2-octylsulfanyloctyl)imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCCSC(CCCCCC)CN1C=CN=C1 CMZZJAGYGMXLAC-UHFFFAOYSA-N 0.000 description 1
- ASGXTCYBWLGQDO-UHFFFAOYSA-N 1-(3-dodecylsulfanylbutyl)imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCCCCCCSC(C)CCN1C=CN=C1 ASGXTCYBWLGQDO-UHFFFAOYSA-N 0.000 description 1
- NQVGPYYVNYVUHG-UHFFFAOYSA-N 1-(3-hexoxyoctyl)imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCOC(CCCCC)CCN1C=CN=C1 NQVGPYYVNYVUHG-UHFFFAOYSA-N 0.000 description 1
- HHNCDFMEWCCCQK-UHFFFAOYSA-N 1-(3-octylsulfanyloctyl)imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCCCSC(CCCCC)CCN1C=CN=C1 HHNCDFMEWCCCQK-UHFFFAOYSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- RAPOJMOLZMASTK-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(4-methoxyphenyl)methylsulfanyl]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(OC)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 RAPOJMOLZMASTK-UHFFFAOYSA-N 0.000 description 1
- NFGDEDLEBCWGTK-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-heptylsulfanylethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C=1C=C(Cl)C=C(Cl)C=1C(SCCCCCCC)CN1C=CN=C1 NFGDEDLEBCWGTK-UHFFFAOYSA-N 0.000 description 1
- UKFRZIVBUUVJOI-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)sulfanyl-2-methylhexyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C=1C=C(Cl)C=C(Cl)C=1SC(C)(CCCC)CN1C=CN=C1 UKFRZIVBUUVJOI-UHFFFAOYSA-N 0.000 description 1
- DDXORDQKGIZAME-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 DDXORDQKGIZAME-UHFFFAOYSA-N 0.000 description 1
- UWPKZAQFOZIPIU-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)methylsulfanyl]octyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C=1C=C(Cl)C=CC=1CSC(CCCCCC)CN1C=CN=C1 UWPKZAQFOZIPIU-UHFFFAOYSA-N 0.000 description 1
- QQFZQHBDFMEHPL-UHFFFAOYSA-N 1-[3-(2,4-dichlorophenyl)-3-hexylsulfanylpropyl]imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=C(Cl)C=C(Cl)C=1C(SCCCCCC)CCN1C=CN=C1 QQFZQHBDFMEHPL-UHFFFAOYSA-N 0.000 description 1
- XUVGXEJUMNGRCJ-UHFFFAOYSA-N 1-[3-(2,4-dichlorophenyl)sulfanylheptyl]imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=C(Cl)C=C(Cl)C=1SC(CCCC)CCN1C=CN=C1 XUVGXEJUMNGRCJ-UHFFFAOYSA-N 0.000 description 1
- LJHUOVPJRIYOJK-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)sulfanyloctyl]imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=C(Cl)C=CC=1SC(CCCCC)CCN1C=CN=C1 LJHUOVPJRIYOJK-UHFFFAOYSA-N 0.000 description 1
- UEAIJKVOUMHSPS-UHFFFAOYSA-N 1-[3-[(4-chlorophenyl)methoxy]octyl]imidazole;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=C(Cl)C=CC=1COC(CCCCC)CCN1C=CN=C1 UEAIJKVOUMHSPS-UHFFFAOYSA-N 0.000 description 1
- NYBOXGPOQVUOPC-UHFFFAOYSA-N 1-[3-[(4-chlorophenyl)methylsulfanyl]octyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C=1C=C(Cl)C=CC=1CSC(CCCCC)CCN1C=CN=C1 NYBOXGPOQVUOPC-UHFFFAOYSA-N 0.000 description 1
- GWMKCWHBDUFJIT-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-2-(4-chlorophenyl)sulfanylbutyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C=CC(Cl)=CC=1)CN1C=NC=C1 GWMKCWHBDUFJIT-UHFFFAOYSA-N 0.000 description 1
- WASVOERPETUABN-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]butyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(OCC=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 WASVOERPETUABN-UHFFFAOYSA-N 0.000 description 1
- VCJXEOATTPQPNH-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-3-[(2-chlorophenyl)methylsulfanyl]butyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CC(SCC=1C(=CC=CC=1)Cl)CCN1C=NC=C1 VCJXEOATTPQPNH-UHFFFAOYSA-N 0.000 description 1
- KEGFDCPNAORZCF-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-4-[(2,4-dichlorophenyl)methoxy]butyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1C(OCC=1C(=CC(Cl)=CC=1)Cl)CCCN1C=NC=C1 KEGFDCPNAORZCF-UHFFFAOYSA-N 0.000 description 1
- OJBDSJBBTHQZMT-UHFFFAOYSA-N 1-[4-[(4-chlorophenyl)methoxy]-4-(2,4-dichlorophenyl)butyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CCCN1C=NC=C1 OJBDSJBBTHQZMT-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 108090000107 Acrosin Proteins 0.000 description 1
- 102100026041 Acrosin Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003315 spermatostatic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/14—Topical contraceptives and spermacides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fertilizers (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/261,411 US4368186A (en) | 1981-05-07 | 1981-05-07 | Methods and compositions for intravaginal contraception |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO821496L true NO821496L (no) | 1982-11-08 |
Family
ID=22993188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO821496A NO821496L (no) | 1981-05-07 | 1982-05-06 | Befruktningshindrende gelpreparat. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4368186A (da) |
| EP (1) | EP0065385A3 (da) |
| JP (1) | JPS57192313A (da) |
| AU (1) | AU8346082A (da) |
| DK (1) | DK203582A (da) |
| FI (1) | FI821600L (da) |
| IL (1) | IL65699A (da) |
| NO (1) | NO821496L (da) |
| ZA (1) | ZA823136B (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588581A (en) * | 1984-11-16 | 1986-05-13 | Basf Corporation | Methods and compositions for intravaginal contraception |
| US4585647A (en) * | 1984-11-19 | 1986-04-29 | Basf Corporation | Methods and compositions for intravaginal contraception |
| CA1331559C (en) | 1986-04-21 | 1994-08-23 | Jon Joseph Kabara | Antimicrobial preservative compositions and methods |
| US5208257A (en) * | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
| FR2598916B1 (fr) * | 1986-05-22 | 1988-09-09 | Atlantic Pharma Prod | Compose chimique fluore utilise dans une methode de contraception locale et composition contraceptive locale fluoree, notamment spermicide |
| ATE64854T1 (de) * | 1986-05-22 | 1991-07-15 | Atlantic Pharma Prod | Zusammensetzung mit hemmender wirkung auf zumindest ein einzelliges lebewesen und/oder virus, herstellungsverfahren und anwendungen dieser zusammensetzung. |
| IT1213323B (it) * | 1986-08-07 | 1989-12-20 | Crinos Industria Farmaco | Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida |
| CA1329614C (en) * | 1987-05-02 | 1994-05-17 | Rainer Buerstinghaus | N-substituted azoles |
| US4904683A (en) * | 1987-06-03 | 1990-02-27 | Janssen Pharmaceutica N.V. | Emulsifiable concentrates containing azoles |
| US5545615A (en) * | 1987-09-18 | 1996-08-13 | Zymogenetics, Inc. | A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III |
| FR2620698B1 (fr) * | 1987-09-23 | 1990-08-10 | Atlantic Pharma Prod | Fluorure d'ammonium quaternaire et son application dans une substance inhibitrice ou destructrice d'etres vivants unicellulaires |
| EP0380084A3 (en) * | 1989-01-27 | 1991-03-13 | The Biomembrane Institute | Method for the inhibition of cell-cell and cell substratum interactions by the blocking of carbohydrate-carbohydrate interactions |
| CA2040460C (en) * | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Drug delivery with thermoreversible gels |
| US5593683A (en) * | 1990-05-01 | 1997-01-14 | Mdv Technologies, Inc. | Method of making thermoreversible polyoxyalkylene gels |
| IT1250748B (it) * | 1991-08-02 | 1995-04-21 | Poli Ind Chimica Spa | Formulazioni utili per il trattamento della secchezza vaginale |
| GR1001412B (el) * | 1992-10-12 | 1993-11-30 | Poli Ind Chimica Spa | Συν?έσεις χρήσιμες δια την ?εραπευτική αγωγή της ξηρότητος του κόλπου. |
| US6051603A (en) * | 1998-01-20 | 2000-04-18 | Wayne Hughes Institute | Vanadium (IV) metallocene complexes having sperm motility inhibiting activity |
| US6432941B1 (en) | 1998-01-20 | 2002-08-13 | Parker Hughes Institute | Vanadium compounds for treating cancer |
| US6245808B1 (en) | 1998-11-05 | 2001-06-12 | Parker Hughes Institute | Oxy-vanadium (IV) complexes having spermicidal activity |
| WO2004075854A2 (en) * | 2003-02-26 | 2004-09-10 | Program For Appropriate Technology In Health | Microbicidal compositions and method of use |
| WO2004105662A1 (en) * | 2003-05-23 | 2004-12-09 | Program For Appropriate Technology In Health | Microbicidal compositions and methods of use |
| JP2007518394A (ja) * | 2003-08-14 | 2007-07-12 | ザ バイオ バランス コーポレイション | 細菌菌株、該細菌菌株を含む組成物、およびそのプロバイオティクス使用 |
| UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| EP1906987B1 (en) | 2005-07-19 | 2011-01-19 | The Population Council, Inc. | Methods and compositions for emergency contraception using endothelin receptor antagonists |
| KR101275814B1 (ko) * | 2006-06-23 | 2013-06-18 | 삼성에스디아이 주식회사 | 분산제 화합물 및 그의 제조방법 |
| BRPI0904249B1 (pt) | 2009-08-28 | 2018-03-06 | Biolab Sanus Farmacêutica Ltda. | Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica |
| JP2013512275A (ja) | 2009-12-01 | 2013-04-11 | セプロックス バイオテック エッセ エッレ | Ｈｉｖ感染予防用ヒドロキシチロソール及び誘導体の局所使用 |
| EP2546358A1 (en) | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Methods and reagents for efficient control of HIV progression |
| EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
| US10016361B2 (en) | 2014-10-24 | 2018-07-10 | Francoise Farron | PH change in the vagina as a contraceptive |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740421A (en) * | 1966-09-19 | 1973-06-19 | Basf Wyandotte Corp | Polyoxyethylene-polyoxypropylene aqueous gels |
| US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4247552A (en) * | 1979-01-11 | 1981-01-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
| US4277475A (en) * | 1979-01-11 | 1981-07-07 | Syntex (U.S.A.) Inc. | Contraceptive methods employing 1-substituted imidazole derivatives |
-
1981
- 1981-05-07 US US06/261,411 patent/US4368186A/en not_active Expired - Fee Related
-
1982
- 1982-05-06 AU AU83460/82A patent/AU8346082A/en not_active Abandoned
- 1982-05-06 DK DK203582A patent/DK203582A/da unknown
- 1982-05-06 ZA ZA823136A patent/ZA823136B/xx unknown
- 1982-05-06 JP JP57075925A patent/JPS57192313A/ja active Pending
- 1982-05-06 EP EP82302311A patent/EP0065385A3/en not_active Withdrawn
- 1982-05-06 NO NO821496A patent/NO821496L/no unknown
- 1982-05-06 FI FI821600A patent/FI821600L/fi not_active Application Discontinuation
- 1982-05-06 IL IL65699A patent/IL65699A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK203582A (da) | 1982-11-08 |
| FI821600L (fi) | 1982-11-08 |
| EP0065385A2 (en) | 1982-11-24 |
| EP0065385A3 (en) | 1983-06-15 |
| IL65699A (en) | 1985-01-31 |
| FI821600A0 (fi) | 1982-05-06 |
| AU8346082A (en) | 1983-11-10 |
| IL65699A0 (en) | 1982-08-31 |
| ZA823136B (en) | 1983-12-28 |
| US4368186A (en) | 1983-01-11 |
| JPS57192313A (en) | 1982-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO821496L (no) | Befruktningshindrende gelpreparat. | |
| US6706276B2 (en) | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa | |
| US5545401A (en) | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine | |
| US4252787A (en) | Anti-fertility composition and method | |
| US8193248B2 (en) | Contraceptive composition | |
| US20130102548A1 (en) | Pharmaceutical delivery system | |
| AU2001243431A1 (en) | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa | |
| US6913759B2 (en) | Gel composition and method for treatment of vaginal infections | |
| US20180280467A1 (en) | Compositions and methods for treating precocious puberty | |
| EA010155B1 (ru) | Вагинальная мукоадгезивная композиция на основе нитрата сертаконазола, фармацевтический набор на основе композиции, фармацевтическая дозированная форма для лечения вульвовагинального кандидоза и способ его лечения | |
| KR20050025166A (ko) | 가온성 및 무자극성 윤활제 항진균성 겔 조성물 | |
| JPS5931714A (ja) | 避妊組成物 | |
| US4585647A (en) | Methods and compositions for intravaginal contraception | |
| Benagiano et al. | Contraceptive devices: intravaginal and intrauterine delivery systems | |
| WO2020011845A1 (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| WO2000053183A1 (en) | Medicament against dysmenorrhoea and premenstrual syndrome | |
| US20030091642A1 (en) | Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof | |
| US7687078B1 (en) | Method of treatment | |
| Homm et al. | ORF 13904, a new long-acting vaginal contraceptive | |
| US20190262361A1 (en) | Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids | |
| ZANEVELD et al. | Properties of a New, Long‐Lasting Vaginal Delivery System (LASRS) for Contraceptive and Antimicrobial Agents | |
| US20240115490A1 (en) | Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof | |
| US20110082128A1 (en) | In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts | |
| WO2001080861A1 (en) | Infertility or increasing fertility |